WO2003028001A8 - Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol - Google Patents
Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol Download PDFInfo
- Publication number
- WO2003028001A8 WO2003028001A8 PCT/KR2002/001780 KR0201780W WO03028001A8 WO 2003028001 A8 WO2003028001 A8 WO 2003028001A8 KR 0201780 W KR0201780 W KR 0201780W WO 03028001 A8 WO03028001 A8 WO 03028001A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flavopiridol
- tnf
- cancer cell
- tnf family
- family proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002334433A AU2002334433A1 (en) | 2001-09-24 | 2002-09-19 | Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010059058A KR20030026069A (en) | 2001-09-24 | 2001-09-24 | Apoptosis-inducing cancer-cell-specific composition by combination with TNF family protein and flavopiridol |
KR2001-0059058 | 2001-09-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003028001A2 WO2003028001A2 (en) | 2003-04-03 |
WO2003028001A8 true WO2003028001A8 (en) | 2003-05-08 |
WO2003028001A3 WO2003028001A3 (en) | 2003-12-04 |
Family
ID=19714614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2002/001780 WO2003028001A2 (en) | 2001-09-24 | 2002-09-19 | Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20030026069A (en) |
AU (1) | AU2002334433A1 (en) |
WO (1) | WO2003028001A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2356880B8 (en) | 2009-08-21 | 2012-10-30 | Universidad De Zaragoza | LIPOSOMES COVERED WITH THE EXTRACELLULAR DOMAIN OF THE APO2L / TRAIL PROTEIN. |
CN107205959B (en) * | 2014-11-07 | 2021-02-12 | 大日本住友制药肿瘤学公司 | Methods of targeting transcriptional control at a super-enhancer region |
AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
CN107849073B (en) | 2015-05-18 | 2020-04-03 | 特雷罗药物股份有限公司 | Avasidil prodrugs with increased bioavailability |
KR20180034538A (en) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | Concurrent therapy for the treatment of cancer |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
MX2019007332A (en) | 2016-12-19 | 2019-11-18 | Tolero Pharmaceuticals Inc | Profiling peptides and methods for sensitivity profiling. |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib |
US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
CN110876741B (en) * | 2019-11-25 | 2020-09-29 | 郑州大学第一附属医院 | GBE1 inhibitor frataxin and application of pharmaceutical composition thereof in preparation of drugs for treating lung adenocarcinoma |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980160A (en) * | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
US6087366A (en) * | 1996-03-07 | 2000-07-11 | The Trustees Of Columbia University In The City Of New York | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death |
US5750495A (en) * | 1996-03-26 | 1998-05-12 | The Regents Of The University Of California | Treatment of cystic disease with TNF-α |
CA2260216A1 (en) * | 1996-07-15 | 1998-01-22 | Bristol-Myers Squibb Company | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase |
-
2001
- 2001-09-24 KR KR1020010059058A patent/KR20030026069A/en not_active Application Discontinuation
-
2002
- 2002-09-19 AU AU2002334433A patent/AU2002334433A1/en not_active Abandoned
- 2002-09-19 WO PCT/KR2002/001780 patent/WO2003028001A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2002334433A1 (en) | 2003-04-07 |
WO2003028001A3 (en) | 2003-12-04 |
WO2003028001A2 (en) | 2003-04-03 |
KR20030026069A (en) | 2003-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005077344A3 (en) | Hydantoin derivatives as inhibitors of cellular necrosis | |
CY1116215T1 (en) | Combination therapy for the therapeutic treatment of Protein Deficiency Disorders | |
EA200500893A1 (en) | TRICYCLIC COMPOUNDS, REPRESENTING PROTECTION KINASE INHIBITORS, TO INCREASE THE EFFECTIVENESS OF ANTI-TUMOR AGENTS AND RADIATIVE THERAPY | |
AU747599C (en) | Antitumor agents | |
CA2505128A1 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
WO2003061768A3 (en) | Use of a compound inactivating the kinase a protein in a composition containing a cosmetically acceptable medium in order to lighten the skin | |
IL187438A0 (en) | Pyrrolopyridine derivatives and pharmaceutical compositions containing the same | |
EP2561874A3 (en) | Pharmaceutical compositions for treating cancer | |
EP2460522A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
GEP20043363B (en) | Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
IL173348A (en) | Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments | |
BR0309343A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions. | |
UY28310A1 (en) | PIRAZOLES AS TUMOR NECROSIS FACTOR INHIBITORS | |
WO2007056264A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally | |
WO2007002836A3 (en) | Methods and compositions for the prevention and treatment of kidney disease | |
BR0309342A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions. | |
WO2003028001A3 (en) | Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol | |
WO2007056263A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously | |
PL342614A1 (en) | Anticarcinogenic drugs | |
WO2003008430A3 (en) | Porphyrin derivatives for photodynamic therapy | |
WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
WO2000001415A3 (en) | Use of inhibitors of protein kinase c epsilon to treat pain | |
WO2004082595A3 (en) | Therapeutic use of tumor necrosis factor-alpha mutein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 11/2003 CLASSEE 14/2003 REPLACE ""A1"" BY ""A2"" AND UNDER ""PUBLISHED"", REPLACE ""WITH INTERNATIONAL SEARCH REPORT"" BY ""WITHOUT INTERNATIONAL SEARCH REPORT"" |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |